Finance

Lists
RLAY:NASDAQ
Relay Therapeutics Inc
$16.12
+1.32%
(+0.21) 1D
$16.19
+0.46% (+0.075)
After hours
Closed: Nov 20, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLAY...
Open
$15.59
High
$16.32
Low
$15.17
Mkt. cap
3.56B
Avg. vol.
2.43M
Volume
3.98M
52-wk high
$21.27
52-wk low
$6.28
EPS
-$1.51
Beta
1.75
Shares outstanding
220.96M
No. of employees
218
Open
$15.59
High
$16.32
Low
$15.17
Mkt. cap
3.56B
Avg. vol.
2.43M
Volume
3.98M
52-wk high
$21.27
52-wk low
$6.28
EPS
-$1.51
Beta
1.75
Shares outstanding
220.96M
No. of employees
218
News stories
From web sources and news partners
About Relay Therapeutics Inc
CEO-
Employees218
Founded2015
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to RLAY in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for RLAY in the last 3 months.
Highest
Current $16.12
$31.00 (+92.31%)
Average
$29.00 (+79.90%)
Lowest
$26.00 (+61.29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+79.9%
11/09/2026
Boris Peaker
JonesTrading
Buy
Maintained
$31.00
+92.3%
11/06/2026
Chi Meng Fong
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
John Newman
Canaccord Genuity
Buy
Maintained
$29.00
+79.9%
11/05/2026
Etzer Darout
Barclays
Buy
Maintained
$30.00
+86.1%
11/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Initiated
$26.00
+61.3%
10/27/2026
Priyanka Grover
J.P. Morgan
Buy
Maintained
$31.00
+92.3%
08/14/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$26.00
+61.3%
08/10/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
08/06/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$31.00
+92.3%
07/20/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$28.00
+73.7%
07/08/2026
Bradley Canino
Guggenheim
Buy
Maintained
$26.00
+61.3%
05/25/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$21.00
+30.3%
05/19/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$26.00
+61.3%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$18.00
+11.7%
05/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$22.00
+36.5%
05/06/2026
Danya Ben-Hail
JonesTrading
Hold
Initiated
$18.00
+11.7%
04/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
7.00M
3.00M
350.00K
-
Cost of goods sold
54.04M
70.56M
76.48M
77.14M
Cost of revenue
54.04M
70.56M
76.48M
77.14M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.59M
11.03M
14.69M
13.11M
Operating expense
13.59M
11.03M
14.69M
13.11M
Total operating expenses
67.63M
81.59M
91.17M
90.24M
Operating income
-60.63M
-78.59M
-90.82M
-90.24M
Other non operating income
30.00K
-53.00K
2.00K
-2.00K
EBT including unusual items
-54.89M
-73.29M
-83.71M
-81.74M
EBT excluding unusual items
-54.89M
-73.29M
-83.71M
-81.74M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-54.89M
-73.29M
-83.71M
-81.74M
Net profit margin
-784.14%
-2,443.03%
-23,916.29%
-
Earnings per share
-0.31
-0.41
-0.41
-0.37
Interest and investment income
5.71M
5.35M
7.12M
8.50M
Interest expense
-
-
-
-
Net interest expenses
5.71M
5.35M
7.12M
8.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
-60.03M
-78.09M
-90.46M
-89.96M
Gain or loss from assets sale
35.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps